CD8A and neoplasm: The results of the combination therapy administered via IMOD showed that the decreased ratio of terminally to progenitor exhausted CD8+ cells (Fig. 7j) could contribute to improved proliferation and polyfunctionality of CD8+ cells in generating durable anti-tumor immunity73,78–80.